Related Experiment Video

Updated: Aug 12, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

New drugs in the treatment of heart failure

L Brown1

  • 1Department of Physiology and Pharmacology, University of Queensland, Australia.

Clinical and Experimental Pharmacology & Physiology
|November 1, 1995
PubMed

Insights

Current heart failure treatments offer limited long-term benefits, with some increasing mortality. Novel vasodilators targeting vasoconstrictors and potentiating vasodilators show promise for improved survival in heart failure patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Current heart failure therapies include diuretics, positive inotropic agents, and vasodilators.
  • While some treatments provide short-term hemodynamic benefits, they may lead to increased mortality.
  • Angiotensin-converting enzyme inhibitors, a class of vasodilators, have demonstrated survival benefits in severe heart failure.

Purpose of the Study:

  • To review current heart failure therapies and their limitations.
  • To explore novel positive inotropic mechanisms, including ion channel modulation and calcium sensitization.
  • To discuss the advancements and future potential of vasodilator therapy in heart failure management.

Main Methods:

  • Literature review of current and emerging heart failure treatments.
  • Analysis of the mechanisms of action for various therapeutic agents.
  • Evaluation of clinical outcomes associated with different treatment strategies.

Main Results:

  • Short-term hemodynamic improvements from certain therapies, like cAMP enhancers, may be offset by long-term risks and increased mortality.
  • Angiotensin-converting enzyme inhibitors represent a class of vasodilators that improve survival in heart failure.
  • Emerging vasodilators target endogenous vasoconstrictors (angiotensin II, endothelin) or potentiate vasodilators (atrial natriuretic factor, nitric oxide).

Conclusions:

  • Traditional heart failure therapies have significant limitations, particularly regarding long-term survival.
  • Novel positive inotropic strategies require further investigation for their therapeutic potential.
  • Advanced vasodilator therapies hold promise for improved heart failure management, but their full potential is yet to be realized.

More Related Videos

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.